SAB Biotherapeutics (SABS) Payables: 2020-2025
Historic Payables for SAB Biotherapeutics (SABS) over the last 4 years, with Sep 2025 value amounting to $6.9 million.
- SAB Biotherapeutics' Payables fell 0.43% to $6.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $25.9 million, marking a year-over-year decrease of 1.59%. This contributed to the annual value of $5.7 million for FY2024, which is 25.75% down from last year.
- Per SAB Biotherapeutics' latest filing, its Payables stood at $6.9 million for Q3 2025, which was down 3.41% from $7.1 million recorded in Q2 2025.
- In the past 5 years, SAB Biotherapeutics' Payables registered a high of $14.3 million during Q4 2021, and its lowest value of $5.7 million during Q2 2024.
- Over the past 3 years, SAB Biotherapeutics' median Payables value was $6.2 million (recorded in 2025), while the average stood at $6.6 million.
- As far as peak fluctuations go, SAB Biotherapeutics' Payables surged by 76.11% in 2021, and later tumbled by 43.08% in 2023.
- Quarterly analysis of 5 years shows SAB Biotherapeutics' Payables stood at $14.3 million in 2021, then dropped by 24.99% to $10.7 million in 2022, then declined by 27.57% to $7.7 million in 2023, then fell by 25.75% to $5.7 million in 2024, then declined by 0.43% to $6.9 million in 2025.
- Its Payables was $6.9 million in Q3 2025, compared to $7.1 million in Q2 2025 and $6.2 million in Q1 2025.